Leora Baumgarten

Meliora Therapeutics, Inc. is an American company that is revolutionizing cancer drug development by utilizing genomics and advanced computational methods as key components of their product development process. The company is based in California. The company has created "molecular fingerprints" for thousands of compounds to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (moa) pairs. This unique discovery engine has the potential for high clinical success. Meliora Therapeutics was founded in 2021 by Jason Sheltzer, Joan Smith, and David Li. David Li has been the CEO since 2021.

Meliora Therapeutics, Inc. is an American company that is revolutionizing cancer drug development by utilizing genomics and advanced computational methods as key components of their product development process. The company is based in California. The company has created "molecular fingerprints" for thousands of compounds to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (moa) pairs. This unique discovery engine has the potential for high clinical success. Meliora Therapeutics was founded in 2021 by Jason Sheltzer, Joan Smith, and David Li. David Li has been the CEO since 2021.

Meliora Therapeutics, Inc. is an American company that is revolutionizing cancer drug development by utilizing genomics and advanced computational methods as key components of their product development process. The company is based in California. The company has created "molecular fingerprints" for thousands of compounds to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (moa) pairs. This unique discovery engine has the potential for high clinical success. Meliora Therapeutics was founded in 2021 by Jason Sheltzer, Joan Smith, and David Li. David Li has been the CEO since 2021.